Saharut Wongkaewkhiaw

Dr. Saharut Wongkaewkhiaw

King Mongkut's Institute of Technology Ladkrabang, Bangkok, Krung Thep Maha Nakhon, Thailand
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Saharut WongkaewkhiawSaharut Wongkaewkhiaw
Saharut Wongkaewkhiaw
AWAmaraporn Wongrakpanich
Amaraporn Wongrakpanich
SKSucheewin Krobthong
Sucheewin Krobthong
WSWitchuda Saengsawang
Witchuda Saengsawang
ACArthit Chairoungdua
Arthit Chairoungdua
NBNittaya Boonmuen
Nittaya Boonmuen
Colorectal cancer is the leading cause of cancer-related deaths worldwide, warranting the urgent need for a new treatment option. Plant-derived nanovesicles containing bioactive compounds represent new therapeutic avenues due to their unique characteristics as natural nanocarriers for bioactive molecules with therapeutic effects. Recent evidence has revealed potential anticancer activity of bioactive compounds from Boesenbergia rotunda (L.) Mansf. (fingerroot). However, the effect and the underlying mechanisms of fingerroot-derived nanovesicles (FDNVs) against colorectal cancer are still unknown. We isolated the nanovesicles from fingerroot and demonstrated their anticancer activity against two colorectal cancer cell lines, HT-29 and HCT116. The IC50 values were 63.9 ± 2.4, 57.8 ± 4.1, 47.8 ± 7.6 μg/ml for HT-29 cells and 57.7 ± 6.6, 47.2 ± 5.2, 34 ± 2.9 μg/ml for HCT116 cells at 24, 48, and 72 h, respectively. Interestingly, FDNVs were not toxic to a normal colon epithelial cell line, CCD 841 CoN. FDNVs exhibited selective uptake by the colorectal cancer cell lines but not the normal colon epithelial cell line. Moreover, dose- and time-dependent FDNV-induced apoptosis was only observed in the colorectal cancer cell lines. In addition, reactive oxygen species levels were substantially increased in colorectal cancer cells, but total glutathione decreased after treatment with FDNVs. Our results show that FDNVs exhibited selective anticancer activity in colorectal cancer cell lines via the disruption of intracellular redox homeostasis and induction of apoptosis, suggesting the utility of FDNVs as a novel intervention for colorectal cancer patients.

16 December 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Saharut WongkaewkhiawSaharut Wongkaewkhiaw
Saharut Wongkaewkhiaw
STSuwimol Taweechaisupapong
Suwimol Taweechaisupapong
STSanguansak Thanaviratananich
Sanguansak Thanaviratananich
JBJan G. M. Bolscher
Jan G. M. Bolscher
KNKamran Nazmi
Kamran Nazmi
SKSakawrat Kanthawong
Sakawrat Kanthawong
Chronic rhinosinusitis (CRS) is a chronic disease that involves long-term inflammation of the nasal cavity and paranasal sinuses. Bacterial biofilms present on the sinus mucosa of certain patients reportedly exhibit resistance against traditional antibiotics, as evidenced by relapse, resulting in severe disease. The aim of this study was to determine the killing activity of human cathelicidin antimicrobial peptides (LL-37, LL-31) and their D-enantiomers (D-LL-37, D-LL-31), alone and in combination with conventional antibiotics (amoxicillin; AMX and tobramycin; TOB), against bacteria grown as biofilm, and to investigate the biological activities of the peptides on human lung epithelial cells. D-LL-31 was the most effective peptide against bacteria under biofilm-stimulating conditions based on IC50 values. The synergistic effect of D-LL-31 with AMX and TOB decreased the IC50 values of antibiotics by 16-fold and could eliminate the biofilm matrix in all tested bacterial strains. D-LL-31 did not cause cytotoxic effects in A549 cells at 25 μM after 24 h of incubation. Moreover, a cytokine array indicated that there was no significant induction of the cytokines involving in immunopathogenesis of CRS in the presence of D-LL-31. However, a tissue-remodeling-associated protein was observed that may prevent the progression of nasal polyposis in CRS patients. Therefore, a combination of D-LL-31 with AMX or TOB may improve the efficacy of currently used antibiotics to kill biofilm-embedded bacteria and eliminate the biofilm matrix. This combination might be clinically applicable for treatment of patients with biofilm-associated CRS.

28 May 2019 in Biofouling
Verified
Journal Article
Closed access
Saharut WongkaewkhiawSaharut Wongkaewkhiaw
Saharut Wongkaewkhiaw
STSuwimol Taweechaisupapong
Suwimol Taweechaisupapong
CAChitchanok Anutrakunchai
Chitchanok Anutrakunchai
KNKamran Nazmi
Kamran Nazmi
JBJan G.M. Bolscher
Jan G.M. Bolscher
SKSakawrat Kanthawong
Sakawrat Kanthawong
Melioidosis is a severe disease caused by Burkholderia pseudomallei. The biofilm of B. pseudomallei acquires resistance to several antibiotics and may be related to relapse in melioidosis patients. Here, the killing activity of antimicrobial peptides (LL-37, LL-31) and the D-enantiomers (D-LL-37, D-LL-31) in combination with ceftazidime (CAZ) against B. pseudomallei 1026b, H777 and a biofilm mutant M10, derived from H777 grown under biofilm-stimulating conditions was observed. Using static conditions, D-LL-31 exhibited the strongest killing activity against the three isolates in a dose-dependent manner. IC50 values for D-LL-31 ranged from 1 to 6 µM, for isolates M10, H777, and 1026b, respectively. Moreover, D-LL-31 combined with CAZ synergistically decreased the IC50 values of the peptide and antibiotic and caused also disruption of biofilms of B. pseudomallei 1026b under flow conditions. Thus a combination of D-LL-31 and CAZ may enhance the efficacy of the currently used antibiotic treatments against B. pseudomallei.

2 January 2024 in Biofouling
Verified
Journal Article
Closed access
MKMintra Khosakueng
Mintra Khosakueng
STSuwimol Taweechaisupapong
Suwimol Taweechaisupapong
WBWongwarut Boonyanugomol
Wongwarut Boonyanugomol
PPPornpan Prapatpong
Pornpan Prapatpong
Saharut WongkaewkhiawSaharut Wongkaewkhiaw
Saharut Wongkaewkhiaw
SKSakawrat Kanthawong
Sakawrat Kanthawong
Chronic rhinosinusitis (CRS) is long-term inflammation of the sinuses that can be caused by infection due to antibiotic-resistant bacteria. Biofilm developed by microbes is postulated to cause antibiotic treatment failure. Thus, the anti-biofilm activities of seven Thai herbal essential oils (EOs) against antibiotic-resistant bacteria isolated from CRS patients was investigated. Lemongrass (Cymbopogon citratus L.) EO showed the most effective antibiofilm activity against Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus epidermidis grown as biofilm. GC-MS analysis found that myrcene was the major bioactive compound. Pretreatment with lemongrass EO significantly inhibited biofilm formation of all bacterial strains in more than 50% of cases. Furthermore, confocal microscopy analysis revealed the biofilm-disrupting activity of lemongrass EO against the biofilm matrix of all these bacterial species and also increased P. aeruginosa swarming motility with no toxicity to human cells. These results suggest that lemongrass EO has promising clinical applications as an anti-biofilm agent for CRS patients.

20 October 2020 in Biofouling
Verified
Journal Article
Open access
Saharut WongkaewkhiawSaharut Wongkaewkhiaw
Saharut Wongkaewkhiaw
SKSakawrat Kanthawong
Sakawrat Kanthawong
JBJan G. M. Bolscher
Jan G. M. Bolscher
KNKamran Nazmi
Kamran Nazmi
STSuwimol Taweechaisupapong
Suwimol Taweechaisupapong
BKBastiaan P. Krom
Bastiaan P. Krom
Chronic rhinosinusitis (CRS) is a chronic infection of the nasal cavity and paranasal sinuses associated with the presence of a microbial biofilm. Extracellular DNA (eDNA) is an important component of the biofilm matrix. Antimicrobial peptides (AMPs) are natural peptides with the ability to kill microorganisms. D-LL-31 is a synthetic variant of the AMP cathelicidin with increased resistance to proteolytic breakdown. In this study it is shown for 3 clinical CRS isolates that treatment of 24 h biofilms with DNase I enhanced the antimicrobial activity of D-LL-31. Conversely, co-incubation of D-LL-31 at the IC50 value with exogenous DNA resulted in reduced antimicrobial activity. DNase I alone did not show antimicrobial activity against the isolates tested but caused dispersal of an established biofilm. Hence, the presence of eDNA in the biofilm matrix reduced AMP-mediated killing. These results suggest that combination therapy with proteolysis resistant AMP D-LL-31 and DNase could be considered for effective treatment of CRS.

30 May 2026 in Scientific Reports
Verified
Journal Article
Open access
NCNattaset Chamnanvinijchai
Nattaset Chamnanvinijchai
NTNicha Techawatcharathep
Nicha Techawatcharathep
NNNatnicha Ngerndee
Natnicha Ngerndee
STSittikorn Teerawongwiwat
Sittikorn Teerawongwiwat
BABoonjira Anukul
Boonjira Anukul
Saharut WongkaewkhiawSaharut Wongkaewkhiaw
Saharut Wongkaewkhiaw
Oral biofilms are major etiological factors in dental caries and periodontitis and are often resistant to conventional anti-microbial therapies, particularly in mixed-species communities. Phytosphingosine (PHS), a naturally occurring bioactive sphingolipid, has demonstrated anti-microbial activity against several pathogens; however, its effects on mixed-species oral biofilms and inflammatory responses remain unclear. This study investigated the in vitro anti-microbial, anti-biofilm, and immunomodulatory activities of PHS against Streptococcus mutans and Aggregatibacter actinomycetemcomitans in single- and dual-species biofilms. Confocal laser scanning microscopy revealed a significant reduction in biofilm matrix formation in both single- and dual-species biofilms treated with PHS compared with untreated controls ( P < 0.001). Cytotoxicity analysis demonstrated that cell viability remained above 90% following exposure to 5 µg/ml PHS for 24 h. Furthermore, PHS pretreatment significantly attenuated LPS-induced IL-6 and TNF-α production ( P < 0.001). Collectively, these findings suggest that PHS is a promising dual-function agent with anti-microbial and anti-inflammatory properties and may have potential as an adjunctive therapeutic strategy for biofilm-associated oral diseases.